Assertio Holdings, Inc..
ASRT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Assertio Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing products primarily in the areas of neurology, pain, and other central nervous system (CNS) conditions. The company acquires, develops, and commercializes differentiated pharmaceutical products. As...Show More
Better Health for All
-60
The company offers co-pay assistance programs for its products. For Otrexup, commercially insured patients can reduce out-of-pocket costs to $0, with a maximum benefit of $250 per prescription for up to 13 fills per calendar year.
1
For Rolvedon, a commercial copay assistance program offers up to $15,000 per 12-month enrollment, with a maximum of $5,500 per script, and a first-cycle patient support program provides a free first dose.
2
However, eligibility for the Otrexup co-pay assistance program excludes patients covered by federal or state healthcare programs (Medicare, Medicaid).
3
For Rolvedon, patient assistance programs target uninsured/underinsured patients with incomes up to 500% of the federal poverty level.
4
The company provides information on potential side effects and administration instructions for Otrexup and details eligibility criteria, limitations, and exclusions for its patient assistance programs.
5
Assertio states a commitment to providing information on product risks and benefits to healthcare professionals and protecting patient privacy with policies in place to avoid unauthorized access.
6
The company also supports healthcare professional education and training.
7
Fair Money & Economic Opportunity
0
Assertio Holdings, Inc. is a specialty pharmaceutical company. The 'Fair Money & Economic Opportunity' value is defined as covering activities that lend, insure, move, or store money. The company's core business of developing and commercializing pharmaceutical products does not fall under this definition. Therefore, all KPIs related to financial services, such as lending, deposit services, APRs, debt products, and financial literacy, are not applicable to Assertio Holdings, Inc. The provided articles discuss pricing and access to medical products, as well as compliance programs, but these do not constitute evidence for the specific financial services activities evaluated by this value's KPIs.
1
Fair Pay & Worker Respect
0
The company has no reported regulatory actions, violations, fines, or compliance issues related to labor laws or human rights.
1
Information regarding living wage coverage, CEO to median employee pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, employee turnover, insecure contract share, or health insurance coverage is not available.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Assertio Holdings, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
The company has a comprehensive whistleblower policy, communicated to all staff, which includes a 24/7 confidential alertline and online reporting portal.
1
The policy explicitly prohibits retaliatory action against employees who report potential violations in good faith, and employees are required to certify their understanding of the Code of Conduct.
2
Assertio maintains an anti-corruption policy that prohibits bribes, kickbacks, or illicit payments in violation of the FCPA, UK Bribery Act, and other anti-corruption laws, applying to all business transactions including foreign countries.
3
However, the policy lacks specific details on risk-based training or third-party due diligence systems. The company has not reported any financial restatements that required a recovery analysis of incentive-based compensation.
4
For complaints, the company requires adverse events or product complaints to be reported within one business day, but the median time to close ethics complaints is not disclosed.
5
Kind to Animals
0
The company conducts animal testing, specifically pre-clinical trials of its drugs on animals, as stated in a press release and noted as a product activity.
1
However, no specific data is provided regarding the percentage of products certified cruelty-free, the extent of non-animal testing methods employed, the percentage of animal-related operations with humane certifications, the measurable impact of conservation initiatives, the percentage of animal-derived ingredients replaced, the percentage of suppliers audited for welfare compliance, the percentage of cage-free sourcing, the strength or scope of any animal testing policy, the number of animals used annually in testing, the percentage of R&D budget invested in animal-free technologies, animal agriculture ethics, participation in animal-free R&D collaborations, or public policy engagement related to animal welfare.
2
Therefore, no KPIs can be scored against the provided rubric thresholds.
No War, No Weapons
0
Assertio Holdings, Inc. is a pharmaceutical company and is explicitly stated to not be involved in defense or military-related industries.
1
Consequently, it derives 0% of its revenue from arms or defense contracts.
2
The company does not develop or sell dual-use technologies with military applications, and there is no defense business for its board to oversee.
3
Furthermore, there is no exposure to any weapons, controversial or otherwise.
4
Planet-Friendly Business
0
No specific, concrete evidence was found in the provided article to assess Assertio Holdings, Inc. against any of the 'Planet-Friendly Business' KPIs. The article focuses on corporate responsibility related to ethical product promotion, healthcare professional relationships, patient safety, access, and privacy, without providing quantitative data or specific actions pertaining to environmental stewardship, emissions, renewable energy, waste, water, or climate-related initiatives.
1
Respect for Cultures & Communities
0
No relevant data regarding ASRT.US's respect for cultures and communities was found in the provided articles. All articles explicitly stated that they contained no quantitative data or specific information pertinent to the company's performance on this ethical value.
1
Safe & Smart Tech
0
No evidence available to assess Assertio Holdings, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points related to Assertio Holdings, Inc.'s performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles.
1
The articles primarily discuss general market trends and industry-wide initiatives in pharmaceutical packaging, or provide a corporate responsibility statement for Assertio Holdings without quantitative data on these metrics.